Found 18 Small Cell Lung Cancer trials
A listing of Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
This is an umbrella study designed to learn more about how well different drugs work in non-small cell lung cancer. This study will test MK-4830, MK7-684, and MK-5890 with pembrolizumab and standard chemotherapy or with pembrolizumab alone in subjects with advanced NSCLC.
MK-7684A-006: Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC
Phase 3
This trial is testing MK-7684A when given in combination with chemotherapy plus radiation therapy (concurrent chemoradiotherapy or cCRT). This trial is for people with stage 3 non-small cell lung cancer (NSCLC). Receiving cCRT is part of the standard treatment for patients with stage 3 NSCLC. MK-7684A, an experimental treatment, is …
A Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-0482, MK-5890, MK-4830) in combination with pembrolizumab based therapy in patients with PD-(L)1 refractory NSCLC in a rolling-arm design
UPCC 16520: A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Phase 1
This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation). Patients with driver mutations in EGFR, ALK, …
Cardiotoxicity in Non-metastatic Lung Cancer Patients Treated with Chemoradiation Therapy: A Prospective Longitudinal Cohort
We propose a prospective longitudinal cohort of radiation therapy cardiotoxicity in in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiation. We will enroll patients prior to start of chemoradiation and follow them with echocardiogram, PET/CT stress test, blood draw, and symptoms/activity surveys for 2 years to …
A Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-7684, MK-5890, MK-4830) in combination with pembrolizumab plus standard chemotherapy in treatment-naïve participants with advanced NSCLC.
PILOT STUDY TO ASSESS LUNG FUNCTION USING PERFUSION BLOOD VOLUME DUAL ENERGY CT AND 4DCT DERIVED LUNG VENTILATION IMAGING
The basic premise of this pilot study is to enroll 40 patients over 1.5 years who have Stage III or IV non-small cell lung cancer and are planned for definitive treatment with concurrent chemoradiation when a contrast-enhanced 4DCT is planned. The primary goal is to quantify the reproducibility of lung …
S2302 - Comparing two treatments for advanced lung cancer: one without chemotherapy (using a combination of drugs called ramucirumab and pembrolizumab), and the other following the usual care after immunotherapy
Phase 3
This study compares the impact of using a combination of drugs, ramucirumab and pembrolizumab, versus standard chemotherapy for treating advanced non-small cell lung cancer that is stage IV or recurrent. Ramucirumab blocks new blood vessel growth that tumors need, while pembrolizumab boosts the immune system to fight cancer. The trial …
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib) a Third Generation EGFR-TKI as Monotherapy or in Combinations With JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Phase 1
the purpose of this study is to see if lazertinib and JNJ-61186372 are safe and useful for treating patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC). Eligible subjects will be those with NSCLC.
LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
This is a screening study to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
1 - 10 of 18
- 1
- 2
